U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H44O7
Molecular Weight 540.6876
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CICLESONIDE

SMILES

[H][C@@]12C[C@H]3O[C@H](O[C@@]3(C(=O)COC(=O)C(C)C)[C@@]1(C)C[C@H](O)[C@@]4([H])[C@@]2([H])CCC5=CC(=O)C=C[C@]45C)C6CCCCC6

InChI

InChIKey=LUKZNWIVRBCLON-GXOBDPJESA-N
InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1

HIDE SMILES / InChI

Molecular Formula C32H44O7
Molecular Weight 540.6876
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12054077

Ciclesonide is a glucocorticoid receptor agonist indicated for the treatment of allergic rhinitis (Omnaris nasal spray) and asthma (Alvesco). It was also developed by Byk Gulden for chronic obstructive pulmonary disease (COPD), but no development had been reported for this indication since 1999. Ciclesonide is a pro-drug and rapidly metabolized to C21-desisobutyryl-ciclesonide which is more potent toward GR receptor than the parent drug.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
OMNARIS

Approved Use

OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older and for the treatment of nasal symptoms associated with perennial allergic rhinitis in adults and adolescents 12 years of age and older.

Launch Date

2006
Palliative
OMNARIS

Approved Use

OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older and for the treatment of nasal symptoms associated with perennial allergic rhinitis in adults and adolescents 12 years of age and older.

Launch Date

2006
Preventing
ALVESCO

Approved Use

Alvesco is an inhaled corticosteroid indicated for: Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older

Launch Date

2008
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
59.2 nM
0.64 mg single, intravenous
dose: 0.64 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CICLESONIDE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.38 h
0.64 mg single, intravenous
dose: 0.64 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CICLESONIDE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
800 μg single, intravenous
dose: 800 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CICLESONIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.64 mg single, intravenous
Dose: 0.64 mg
Route: intravenous
Route: single
Dose: 0.64 mg
Sources:
healthy, 27.3 years (range: 19-40 years)
n = 6
Health Status: healthy
Age Group: 27.3 years (range: 19-40 years)
Sex: M
Population Size: 6
Sources:
6.9 mg single, oral
Dose: 6.9 mg
Route: oral
Route: single
Dose: 6.9 mg
Sources:
healthy, 27.3 years (range: 19-40 years)
n = 6
Health Status: healthy
Age Group: 27.3 years (range: 19-40 years)
Sex: M
Population Size: 6
Sources:
640 ug 2 times / day multiple, respiratory
Highest studied dose
Dose: 640 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 640 ug, 2 times / day
Sources: Page: p. 133
unhealthy, 48.3 years (range: 17-70 years)
Health Status: unhealthy
Age Group: 48.3 years (range: 17-70 years)
Sex: M+F
Sources: Page: p. 133
10 mg single, oral
Highest studied dose
Dose: 10 mg
Route: oral
Route: single
Dose: 10 mg
Sources:
healthy, adult
282 ug 1 times / day multiple, intranasal
Highest studied dose
Dose: 282 ug, 1 times / day
Route: intranasal
Route: multiple
Dose: 282 ug, 1 times / day
Sources: Page: p.42
unhealthy, adult
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: adult
Sources: Page: p.42
Disc. AE: Burning sensation...
AEs leading to
discontinuation/dose reduction:
Burning sensation (severe, 1 patient)
Sources: Page: p.42
2880 ug single, respiratory
Highest studied dose
Dose: 2880 ug
Route: respiratory
Route: single
Dose: 2880 ug
Sources:
healthy, adult
100 ug 1 times / day steady, respiratory
Dose: 100 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 100 ug, 1 times / day
Sources:
unhealthy, children
n = 79
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 79
Sources:
Other AEs: Lobar pneumonia, Asthma...
Other AEs:
Lobar pneumonia (serious, 1 patient)
Asthma (serious, 1 patient)
Pyrexia (below serious, 6 patients)
Ear infection (below serious, 5 patients)
Pharyngitis (below serious, 5 patients)
Rhinitis (below serious, 4 patients)
Upper respiratory tract infection (below serious, 18 patients)
Cough (below serious, 6 patients)
Allergic rhinitis (below serious, 7 patients)
Sources:
200 ug 1 times / day steady, respiratory
Dose: 200 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy, children
n = 76
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 76
Sources:
Other AEs: Laryngitis, Epistaxis...
Other AEs:
Laryngitis (serious, 1 patient)
Epistaxis (serious, 1 patient)
Myringoplasty (serious, 1 patient)
Ear infection (below serious, 3 patients)
Influenza (below serious, 6 patients)
Lower respiratory tract infection (below serious, 4 patients)
Upper respiratory tract infection (below serious, 19 patients)
Cough (below serious, 4 patients)
Sources:
200 ug 1 times / day steady, respiratory
Dose: 200 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy
n = 40
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Population Size: 40
Sources:
Other AEs: Cough, Asthenia...
Other AEs:
Cough (below serious, 2 patients)
Asthenia (below serious, 1 patient)
Chest pain (below serious, 1 patient)
Decreased activity (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Burning sensation severe, 1 patient
Disc. AE
282 ug 1 times / day multiple, intranasal
Highest studied dose
Dose: 282 ug, 1 times / day
Route: intranasal
Route: multiple
Dose: 282 ug, 1 times / day
Sources: Page: p.42
unhealthy, adult
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: adult
Sources: Page: p.42
Upper respiratory tract infection below serious, 18 patients
100 ug 1 times / day steady, respiratory
Dose: 100 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 100 ug, 1 times / day
Sources:
unhealthy, children
n = 79
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 79
Sources:
Rhinitis below serious, 4 patients
100 ug 1 times / day steady, respiratory
Dose: 100 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 100 ug, 1 times / day
Sources:
unhealthy, children
n = 79
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 79
Sources:
Ear infection below serious, 5 patients
100 ug 1 times / day steady, respiratory
Dose: 100 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 100 ug, 1 times / day
Sources:
unhealthy, children
n = 79
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 79
Sources:
Pharyngitis below serious, 5 patients
100 ug 1 times / day steady, respiratory
Dose: 100 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 100 ug, 1 times / day
Sources:
unhealthy, children
n = 79
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 79
Sources:
Cough below serious, 6 patients
100 ug 1 times / day steady, respiratory
Dose: 100 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 100 ug, 1 times / day
Sources:
unhealthy, children
n = 79
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 79
Sources:
Pyrexia below serious, 6 patients
100 ug 1 times / day steady, respiratory
Dose: 100 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 100 ug, 1 times / day
Sources:
unhealthy, children
n = 79
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 79
Sources:
Allergic rhinitis below serious, 7 patients
100 ug 1 times / day steady, respiratory
Dose: 100 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 100 ug, 1 times / day
Sources:
unhealthy, children
n = 79
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 79
Sources:
Asthma serious, 1 patient
100 ug 1 times / day steady, respiratory
Dose: 100 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 100 ug, 1 times / day
Sources:
unhealthy, children
n = 79
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 79
Sources:
Lobar pneumonia serious, 1 patient
100 ug 1 times / day steady, respiratory
Dose: 100 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 100 ug, 1 times / day
Sources:
unhealthy, children
n = 79
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 79
Sources:
Upper respiratory tract infection below serious, 19 patients
200 ug 1 times / day steady, respiratory
Dose: 200 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy, children
n = 76
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 76
Sources:
Ear infection below serious, 3 patients
200 ug 1 times / day steady, respiratory
Dose: 200 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy, children
n = 76
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 76
Sources:
Cough below serious, 4 patients
200 ug 1 times / day steady, respiratory
Dose: 200 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy, children
n = 76
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 76
Sources:
Lower respiratory tract infection below serious, 4 patients
200 ug 1 times / day steady, respiratory
Dose: 200 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy, children
n = 76
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 76
Sources:
Influenza below serious, 6 patients
200 ug 1 times / day steady, respiratory
Dose: 200 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy, children
n = 76
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 76
Sources:
Epistaxis serious, 1 patient
200 ug 1 times / day steady, respiratory
Dose: 200 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy, children
n = 76
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 76
Sources:
Laryngitis serious, 1 patient
200 ug 1 times / day steady, respiratory
Dose: 200 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy, children
n = 76
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 76
Sources:
Myringoplasty serious, 1 patient
200 ug 1 times / day steady, respiratory
Dose: 200 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy, children
n = 76
Health Status: unhealthy
Condition: asthma
Age Group: children
Population Size: 76
Sources:
Asthenia below serious, 1 patient
200 ug 1 times / day steady, respiratory
Dose: 200 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy
n = 40
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Population Size: 40
Sources:
Chest pain below serious, 1 patient
200 ug 1 times / day steady, respiratory
Dose: 200 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy
n = 40
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Population Size: 40
Sources:
Decreased activity below serious, 1 patient
200 ug 1 times / day steady, respiratory
Dose: 200 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy
n = 40
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Population Size: 40
Sources:
Cough below serious, 2 patients
200 ug 1 times / day steady, respiratory
Dose: 200 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy
n = 40
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Population Size: 40
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
yes [IC50 0.734 uM]
yes [IC50 2.4 uM]
yes [Inhibition 3 uM]
yes [Inhibition 3 uM]
yes
yes
yes
Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide.
2002 May
[Bronchial asthma. A new steroid acts fast and directly].
2003 Dec 4
Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects.
2004
In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide.
2004 Apr
Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide.
2005
Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma.
2005 Apr
[Ciclesonide in the treatment of patients with bronchial asthma].
2005 Dec
Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma.
2005 Feb
Lack of pharmacokinetic drug-drug interaction between ciclesonide and erythromycin.
2005 Jun
Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma.
2005 Mar
Effects of ciclesonide and fluticasone propionate on allergen-induced airway inflammation and remodeling features.
2005 May
Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide.
2005 May
Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects.
2005 May
Properties of the ideal corticosteroid therapy.
2005 May-Jun
[Ciclesonide -- a new inhaled corticosteroid].
2005 Oct
Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes.
2005 Oct-Dec
Gateways to clinical trials.
2005 Sep
Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma.
2005 Sep
Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model.
2005 Sep-Oct
Gateways to clinical trials.
2006 Apr
Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis.
2006 Apr
Systemic side effects of inhaled corticosteroids in patients with asthma.
2006 Aug
Modulation of p-glycoprotein and breast cancer resistance protein by some prescribed corticosteroids.
2006 Feb 15
Gateways to clinical trials.
2006 Jan-Feb
Gateways to clinical trials.
2006 Jul-Aug
A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma.
2006 Jun
Gateways to clinical trials.
2006 Jun
In Vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices.
2006 May
Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma.
2006 May
Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis.
2006 Nov
A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma.
2006 Oct
Gateways to clinical trials.
2006 Sep
In vitro activation of the corticosteroid ciclesonide in animal nasal mucosal homogenates.
2007 Mar
Patents

Sample Use Guides

Allergic rhinitis: The recommended dose of ciclesonide (in form of Omnaris Nasal Spray) is 200 ug per day administered as 2 sprays (50 mcg/spray) in each nostril once daily. Asthma: 80-320 ug twice daily.
Route of Administration: Other
Ciclesonide at 10(-12)–10(-5) M significantly inhibited TNF-alpha stimulated MCP-1 production in human airway smooth muscle cells. IL1-stimulated MCP-1 release was also significantly inhibited in a concentration-dependent (10(-12)–10(-5) M) manner.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:28:15 GMT 2023
Edited
by admin
on Fri Dec 15 16:28:15 GMT 2023
Record UNII
S59502J185
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CICLESONIDE
INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
CICLESONIDE [EP MONOGRAPH]
Common Name English
ciclesonide [INN]
Common Name English
CICLESONIDE [MI]
Common Name English
CICLESONIDE [MART.]
Common Name English
(11β,16α)-16,17-[[(R)-Cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-diene-3,20-dione
Systematic Name English
OMNARIS
Brand Name English
PREGNA-1,4-DIENE-3,20-DIONE, 16,17-(((R)-CYCLOHEXYLMETHYLENE)BIS(OXY))-11-HYDROXY-21-(2-METHYL-1-OXOPROPOXY)-, (11.BETA.,16.ALPHA.)
Common Name English
CICLESONIDE [ORANGE BOOK]
Common Name English
BI54903
Code English
CICLESONIDE [VANDF]
Common Name English
ZETONNA
Brand Name English
RPR-251526
Code English
CICLESONIDE [JAN]
Common Name English
Ciclesonide [WHO-DD]
Common Name English
RPR251526
Code English
CICLESONIDE [USAN]
Common Name English
ALVESCO
Brand Name English
Classification Tree Code System Code
WHO-ATC R03BA08
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
WHO-ATC R01AD13
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
NCI_THESAURUS C521
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
WHO-VATC QR03BA08
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
WHO-VATC QR01AD13
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
Code System Code Type Description
USAN
PP-61
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY
DAILYMED
S59502J185
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY
MERCK INDEX
m3536
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL2040682
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY
DRUG CENTRAL
633
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY
WIKIPEDIA
CICLESONIDE
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY
INN
6546
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY
NCI_THESAURUS
C65326
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY
CAS
126544-47-6
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY
PUBCHEM
6918155
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY
FDA UNII
S59502J185
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY
EVMPD
SUB06236MIG
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY
MESH
C120481
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY
LACTMED
Ciclesonide
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY
EPA CompTox
DTXSID9046659
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY
SMS_ID
100000081904
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY
DRUG BANK
DB01410
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY
CAS
141845-82-1
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
ALTERNATIVE
IUPHAR
7469
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY
RXCUI
274964
Created by admin on Fri Dec 15 16:28:15 GMT 2023 , Edited by admin on Fri Dec 15 16:28:15 GMT 2023
PRIMARY RxNorm
Related Record Type Details
TARGET -> AGONIST
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
MAJOR
METABOLIC ENZYME -> SUBSTRATE
MINOR
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
Des-ciclesonide has anti-inflammatory activity with affinity for the glucocorticoid receptor that is 120 times higher than the parent compound.
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC INTRAVENOUS ADMINISTRATION

ORAL BIOAVAILABILITY PHARMACOKINETIC